FDA Approval Decision on Mavacamtem Moved Out To April 2022

November 20, 2021

The decision on the fate of the novel therapy for hypertrophic cardiomyopathy was delayed because the agency said it needed more time to consider the risk evaluation and mitigation strategy (REMS) for the drug.

Disease-associated Genetic Variants Common Among Those With Early-onset Afib, Study Finds

October 06, 2021

1 in 10 patients with early-onset atrial fibrillation have gene variants associated with a cardiac disease, most commonly some form of cardiomyopathy, according to research conducted by Vanderbilt researchers. Results would justify routinizing genetic testing of young afib patients, the researchers said.

HCM Patients Experience Cardiovascular Comorbidities

September 24, 2021

A company developing a new therapy for hypertrophic cardiomyopathy released data recently showing that people with the obstructive form of the disease often develop hypertension, atrial fibrillation and other forms of cardiovascular disease.